Legend Biotech Corp ADR (NASDAQ: LEGN) has seen a decline in its stock price by -2.57 in relation to its previous close of 48.73. However, the company has experienced a 4.90% gain in its stock price over the last five trading sessions. benzinga.com reported 2024-09-30 that Friday, Legend Biotech Corporation LEGN and Johnson & Johnson JNJ announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study.
Is It Worth Investing in Legend Biotech Corp ADR (NASDAQ: LEGN) Right Now?
Moreover, the 36-month beta value for LEGN is 0.10. Analysts have varying opinions on the stock, with 15 analysts rating it as a “buy,” 7 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LEGN is 181.45M and currently, short sellers hold a 5.77% of that float. On October 02, 2024, LEGN’s average trading volume was 946.89K shares.
LEGN’s Market Performance
LEGN’s stock has seen a 4.90% increase for the week, with a -17.50% drop in the past month and a 6.12% gain in the past quarter. The volatility ratio for the week is 6.27%, and the volatility levels for the past 30 days are at 5.02% for Legend Biotech Corp ADR The simple moving average for the last 20 days is -4.97% for LEGN stock, with a simple moving average of -11.41% for the last 200 days.
Analysts’ Opinion of LEGN
Many brokerage firms have already submitted their reports for LEGN stocks, with Truist repeating the rating for LEGN by listing it as a “Buy.” The predicted price for LEGN in the upcoming period, according to Truist is $88 based on the research report published on June 17, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LEGN reach a price target of $73, previously predicting the price at $86. The rating they have provided for LEGN stocks is “Buy” according to the report published on May 24th, 2024.
Deutsche Bank gave a rating of “Buy” to LEGN, setting the target price at $60 in the report published on May 23rd of the current year.
LEGN Trading at -12.07% from the 50-Day Moving Average
After a stumble in the market that brought LEGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.92% of loss for the given period.
Volatility was left at 5.02%, however, over the last 30 days, the volatility rate increased by 6.27%, as shares sank -17.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.43% lower at present.
During the last 5 trading sessions, LEGN rose by +4.90%, which changed the moving average for the period of 200-days by -21.43% in comparison to the 20-day moving average, which settled at $49.47. In addition, Legend Biotech Corp ADR saw -21.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LEGN starting from Huang Ying, who proposed sale 1,504 shares at the price of $44.10 back on Sep 25 ’24. After this action, Huang Ying now owns shares of Legend Biotech Corp ADR, valued at $66,326 using the latest closing price.
Macomber Lori, the Officer of Legend Biotech Corp ADR, proposed sale 90,060 shares at $48.91 during a trade that took place back on Sep 20 ’24, which means that Macomber Lori is holding shares at $4,405,003 based on the most recent closing price.
Stock Fundamentals for LEGN
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.57 for the gross margin
The net margin for Legend Biotech Corp ADR stands at -0.63. The total capital return value is set at -0.23. Equity return is now at value -22.21, with -15.29 for asset returns.
Based on Legend Biotech Corp ADR (LEGN), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -0.47. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -15.49.
Currently, EBITDA for the company is -421.76 million with net debt to EBITDA at -0.42. When we switch over and look at the enterprise to sales, we see a ratio of 19.37. The receivables turnover for the company is 4.5for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.84.
Conclusion
To wrap up, the performance of Legend Biotech Corp ADR (LEGN) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
